Ipsen is a global specialty-driven biotechnology group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology.
Ipsen’s decision to launch in Canada in January, 2015 is based on the world-class research and clinical development taking place at leading institutions in Canada and in particular in the GTA. Today, Canada is a top ten market for the pharmaceutical industry and Ipsen is committed to being a partner in the Canadian healthcare system.
Contact
5060 Spectrum Way, 5th Floor, Mississauga, ON, L4W 5N5, Canada
Website http://ipsen.ca/about/
Email info.canada@ipsen.com
Lyndal Walker of Ipsen Canada discusses the opportunities present in the Canadian pharma market for a mid-cap innovator like Ipsen, the value of Canada’s research ecosystem, and emerging healthcare trends…
After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that…
Greece is a middling performer in terms of clinical trial numbers on the European stage, nestled next to Finland and Romania on total trial numbers between 2002 and 2020 but…
Ipsen’s George Carystinos explains what brought him back to Greece for a first country manager position after a succession of global roles, how the company’s global specialty care transformation is…
The European Union’s decision to mitigate the effects of the COVID-19 pandemic by launching its Recovery and Resilience Facility (RRF) and moving away from its past austerity policies is particularly…
As the largest pharma market in MEA in terms of volume and second only behind Saudi in value, Egypt is an increasingly important part of pharma multinationals’ MEA operations. Here,…
General manager of MEA, Khaled Elrefae, explains how Ipsen has strengthened its footprint in the region over the past two years – starting in the UAE and expanding into Saudi…
Recent announcements from Ipsen and AbbVie of multimillion Euro investments into Irish manufacturing plants underline the Celtic nation’s continuing attractiveness to pharma multinationals. While an upcoming hike in Ireland’s famously…
Pharma companies no longer view digital as a “nice to have” add on, but as an integral part of their business, yet there are still quite a few hurdles to…
Italy, Europe’s fourth largest pharma market at a size of EUR 23.446 billion, has a highly decentralised healthcare system, with the country’s 20 regions negotiating market access for medicines individually…
See our Cookie Privacy Policy Here
